Proposal of New Imaging Criteria for Evaluating the Response of Liver Metastases to Systemic Treatments in Digestive Neuroendocrine Tumors (NET) as an Alternative to RECIST 1.1
Introduction: RECIST 1.1 criteria have been challenged for the evaluation of treatment response in NET.
Aim(s): To explore alternative computed tomography (CT) response evaluation criteria in metastatic NET.
Materials and methods: We included patients with small-intestine (n=50) or pancreatic (n=54) well-differentiated NET with liver metastases (LM), who received systemic therapy as first two treatment lines in 14 expert centers. Baseline (+/- 1 month) and first reevaluation (within 6 months) contrast-enhanced CT scans were locally reviewed to measure LM diameter (5 LM) and density (arterial and portal phases, 2 LM). Multivariate Cox regression analyses explored which response criteria best correlated with progression-free survival (PFS), considering different thresholds of size or density decrease (10%, 20% or 30%) and number of measured LM (2, 3 or 5).
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.